Novartis AG (SWX:NOVN)
Switzerland
· Delayed Price · Currency is CHF 98.62
+0.33 (0.34%)
Mar 28, 2025, 6:45 PM CET
Novartis AG Revenue
In the year 2024, Novartis AG had annual revenue of $51.72B USD with 10.85% growth. Novartis AG had revenue of $13.56B in the quarter ending December 31, 2024, with 15.13% growth.
Revenue
$51.72B
Revenue Growth
+10.85%
P/S Ratio
4.25
Revenue / Employee
$681.60K
Employees
75,883
Market Cap
187.14B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNovartis AG News
- 2 hours ago - FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer - GlobeNewsWire
- 3 days ago - Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis - GlobeNewsWire
- 7 days ago - FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease - Benzinga
- 7 days ago - Novartis receives third FDA approval for oral Fabhalta treatment for kidney disease C3G - Seeking Alpha
- 7 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G) - PRNewsWire
- 7 days ago - Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) - GlobeNewsWire
- 8 days ago - Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga
- 8 days ago - PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - Benzinga